New drug duo targets tough lung cancers in early trial
NCT ID NCT05879978
First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 29 times
Summary
This early-phase study tests a new combination of two drugs, obrixtamig and ezabenlimab, in adults with advanced small cell lung cancer or other neuroendocrine tumors that have not responded to prior treatments. The main goal is to find the highest safe dose of obrixtamig when given with ezabenlimab. Participants receive the drugs through an IV and are monitored closely for up to 3 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CTR François Baclesse
Caen, 14000, France
-
Cliniques Universitaires Saint-Luc
Brussels, 1200, Belgium
-
Hôpital Louis Pradel
Bron, 69677, France
-
INS Claudius Regaud IUCT-Oncopole
Toulouse, 31059, France
-
National Cancer Center Hospital
Tokyo, Chuo-ku, 104-0045, Japan
-
Technische Universität Dresden
Dresden, 01307, Germany
-
Universitair Ziekenhuis Gent
Ghent, 9000, Belgium
-
Universitätsklinikum Frankfurt
Frankfurt, 60590, Germany
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.